ARTICLE | Clinical News
Verona begins PK trial for RPL554 in healthy volunteers
June 9, 2017 3:15 AM UTC
Verona Pharma plc (LSE:VRP; NASDAQ:VRNA) began a 2-way crossover, U.S. trial to evaluate the bioavailability, pharmacokinetics and safety of nebulized RPL554 in 12 healthy volunteers. Data from the trial are expected in 4Q17.
The nebulized dual phosphodiesterase-3 (PDE-3) and PDE-4 inhibitor is in Phase II testing for chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF) and asthma...